Annals of Internal Medicine is published by the American College of Physicians on the first and third Tuesday of every month. These highlights are not intended to substitute for articles as sources of information. For an embargoed copy of an article, call 1-800-523-1546, ext. 2656, or 215-351-2656. Past highlights are accessible as well.
(Clinical Guidelines, p. 854.)
(Review, p. 840, Editorial, p. 880)
(Academia and Clinic, p. 876.)
This paper is being released early online at the Web site of Annals of Internal Medicine, www.annals.org. It will appear in the Feb. 5, 2008, print edition of the journal.
Experts say current clinical evidence implies that benefits of drug-eluting stents probably outweigh risks, even for patients with complex lesions; but "larger prospective studies with adequate power to detect small differences in stent thrombosis, MI and mortality rates are required." Meanwhile all patients should be screened before any coronary intervention to be sure they can tolerate uninterrupted dual anti-platelet therapy for a minimum of three to six months and preferably one year.
Note: This paper is being released early online at the Web site of Annals of Internal Medicine, www.annals.org. It will appear in the Feb. 5, 2008, print edition of the journal.